The First Department of Internal Medicine,
Faculty of Medicine, University of the Ryukyus, 903-01 Okinawa, Japan
Received 2 September 1997/Returned for modification 15 October
1997/Accepted 20 January 1998
We developed a new simple assay for the quantitation of the
activities of drugs against intracellular Legionella
pneumophila. The cells of a murine macrophage-like cell line
(J774.1 cells) allowed the intracellular growth and replication of the
bacteria, which ultimately resulted in cell death. The infected J774.1
cell monolayers in 96-well microplates were first treated with
antibiotics and were further cultured for 72 h. The number of
viable J774.1 cells in each well was quantified by a colorimetric assay
with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and an enzyme-linked immunosorbent assay reader. The number of growing
bacteria in each well was also determined by counting the numbers of
CFU on buffered charcoal yeast extract-
agar plates. Viable J774.1
cell counts, determined by the colorimetric assay, were inversely
proportional to the number of intracellular replicating bacteria. The
minimum extracellular concentrations (MIECs) of 24 antibiotics causing
inhibition of intracellular growth of L. pneumophila were
determined by the colorimetric assay system. The MIECs of beta-lactams
and aminoglycosides were markedly higher than the MICs in buffered
yeast extract-
broth. The MIECs of macrolides, fluoroquinolones,
rifampin, and minocycline were similar to the respective MICs.
According to their intracellular activities, clarithromycin and
sparfloxacin were the most potent among the macrolides or
fluoroquinolones tested in this study. Our results indicated that the
MTT assay system allows comparative and quantitative evaluations of the
intracellular activities of antibiotics and efficient processing of a
large number of samples.
 |
INTRODUCTION |
Legionella pneumophila is
a facultative intracellular pathogen known to cause both
community-acquired pneumonia (9, 22) and nosocomial
pneumonia (23) of variable severity, including fatal
infections (1). The pathogenesis of Legionella
infections is due to the survival and replication of the microorganism
within phagocytic cells (20) as well as to the cytotoxic
by-products resulting from the intracellular multiplication of the
bacteria (3). These facts, together with clinical
observations (4), suggest that effective treatment of
Legionella infections requires the use of drugs active
against both intracellular and extracellular bacteria. Furthermore,
laboratory evaluation of the activities of drugs against
Legionella spp. should include determination of their
intracellular activities against the bacteria (4), in
addition to determination of the MICs. Unfortunately, in contrast to
MIC determinations, most assays for the activities of drugs against
intraphagocytic Legionella are laborious and expensive and
are not usually quantitative or suitable for use in comparative studies
of several antibiotics. As an indicator of the intracellular activity
of a drug, the minimum extracellular concentration (MIEC) inhibiting
intracellular multiplication has been described previously (31), but the technique used to determine intracellular
bacterial growth involves counting of the numbers of CFU and is
time-consuming.
In this report we describe a simple quantitative method for measuring
the intracellular activities of drugs against L. pneumophila by a colorimetric assay of the remaining J774.1 cells infected with
L. pneumophila.
 |
MATERIALS AND METHODS |
Bacterial strains.
L. pneumophila serogroup 1 (SG1) 80-045 was isolated from the first patient in Japan identified to
have Legionnaires' disease (30). The other strains used in
this study were isolated in our laboratory from the bronchial wash
specimens of different patients with pneumonia. These strains were kept
in sterile skim milk supplemented with 1% (wt/vol) sodium glutamate at
80°C. The clinical isolates were identified as L. pneumophila SG1 by their biochemical profile, the results of slide
agglutination tests with polyclonal rabbit antibodies (Denka Seiken,
Osaka, Japan), and the DNA hybridization technique with
photobiotin-labeled bacterial DNA (8). The bacteria were
first cultured on buffered charcoal yeast extract-
(BCYE-
; Difco
Laboratories, Detroit, Mich.) plates at 35°C for 72 h and were
then suspended at 1.5 × 108 CFU/ml in 5 ml of
buffered yeast extract supplemented with
-ketoglutarate (BYE-
)
broth (5) and incubated at 35°C with vigorous shaking for
12 h. The bacteria were harvested by centrifugation at 3,000 rpm
for 20 min and were resuspended in sterile pyrogen-free distilled water; their concentration was adjusted to approximately 2.9 × 108 CFU/ml.
Reagents and antimicrobial agents.
Yellow tetrazolium salt,
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), was
purchased from Research Organics (Cleveland, Ohio). Levofloxacin
(Dai-ichi Pharmaceutical Co., Tokyo, Japan), ciprofloxacin (Bayer
Pharmaceuticals Japan, Tokyo, Japan), sparfloxacin (Dainippon
Pharmaceuticals, Osaka, Japan), erythromycin base (Dainippon
Pharmaceuticals), clarithromycin (Taisho Pharmaceutical Co., Tokyo,
Japan); roxithromycin (Nippon Roussel Co., Tokyo, Japan), azithromycin
(Pfizer Pharmaceuticals Japan, Tokyo, Japan), and ceftizoxime (Fujisawa
Pharmaceuticals, Osaka, Japan) were donated by the respective
commercial suppliers. Other antimicrobial agents were also donated by
respective commercial suppliers.
MICs.
The MICs of the antimicrobial agents were determined
by the microdilution method (25) in BYE-
broth. For this
purpose, the bacteria were inoculated with a MIC-2000 inoculator
(Dynatech Laboratories Inc., Alexandria, Va.) into 100 µl of BYE-
broth containing serial dilutions of the antibiotics in the wells of a
microtiter plate (inoculum size, 105 CFU/well). The MIC was
defined as the minimum concentration of the drug that inhibited visible
bacterial growth after culture at 35°C for 2 days.
Cell line.
The cells of a murine macrophage-like cell line
(J774.1 cells) were suspended in a mixture of 10% dimethyl sulfoxide
and 90% fetal calf serum (FCS; Whittaker, Walkersville, Md.) and
stocked in liquid nitrogen. An aliquot of the J774.1 cell suspension
was thawed and cultured in a medium consisting of RPMI 1640 (pH 7.2; Gibco Laboratories, Grand Island, N.Y.), 10 mM HEPES (Dojin Chemicals Co. Ltd., Kumamoto, Japan), and 10% heat-inactivated FCS (Whittaker) in a 75-cm2 culture flask (Falcon 3084; Nippon Becton
Dickinson Co., Tokyo, Japan) in humidified air with 5% CO2
at 37°C. The cells were harvested at the logarithmic growth phase and
were suspended in RPMI 1640 medium at 2 × 105
cells/ml. In the next step, 100 µl of the cell suspension was allowed
to adhere to a 96-well flat-bottom tissue culture plate (Falcon 3072;
Becton Dickinson, Lincoln Park, N.J.) in humidified air with 5%
CO2 at 37°C for 12 h.
Infection of J774.1 cells.
Cultured cell monolayers in
96-well microplates were infected with various concentrations of
bacteria suspended in RPMI 1640 medium containing 5% FCS and were
incubated for 12 h. In the next step, the extracellular fluid and
bacteria were removed by decanting the contents of the microplate
containing Legionella-infected J774.1 cell monolayers, and
then antimicrobial agents were added to the wells and the plate was
incubated for an additional 72 h. Finally, the infected cell
monolayer and the supernatant in each well were harvested in 9.8 ml of
sterile distilled water, and the mixture was then vortexed for 20 s to lyse the cells completely and to prevent an antibiotic carryover
effect. These bacterial suspensions were appropriately diluted, and
aliquots (50 µl) of the dilutions were inoculated onto BCYE-
agar.
The number of viable Legionella in each well was determined
by counting the CFU after incubation at 35°C for 3 days.
DFA staining.
After culture of J774.1 cells on sterile
chamber slides (Nalge Nunc International, Naperville, Ill.) in 5%
CO2-air at 37°C, they were infected with bacteria for
12 h as described above. The infected cells were cultured in fresh
RPMI 1640 medium without any antibiotics for an additional 0, 36, or
72 h. The upper structure of the chamber slide was removed
according to the instructions provided by the manufacturer, and the
cell monolayers were fixed in ethanol for at least 5 min to allow the
antibody to penetrate the macrophage membrane (26). The
monolayers were then stained with fluorescein-conjugated anti-L.
pneumophila rabbit polyclonal antibody (MerDx, Scotch Plains,
N.J.) for 30 min in humidified air at 35°C, washed sufficiently with
10 mM phosphate-buffered saline (pH 7.4), and observed with a confocal
laser scanning microscope (Fluoview; Olympus Co. Ltd., Tokyo, Japan).
Colorimetric assay of remaining J774.1 cells.
After
incubation of the J774.1 cells with the bacteria for 72 h, the
remaining J774.1 macrophages were quantified by the rapid colorimetric
assay by the tetrazolium dye procedure (2, 27), with minor
modifications. The contents of the plate were decanted to remove the
supernatants, the extracellular bacteria, and the lysed macrophages.
Then, 100 µl of RPMI 1640 medium containing 5% FCS and 0.5 µg of
MTT per ml was added to each well of the plate. After incubation at
37°C in humidified air with 5% CO2 for 90 min, the
supernatants were removed and 100 µl of isopropyl alcohol containing
0.4 N HCl and 0.5% sodium dodecyl sulfate was added to each well.
After vigorous shaking of the microplates to lyse the cell monolayers,
the optical density of each well was measured at 550 nm with an
automatic plate reader.
Viable Legionella cells also can cleave MTT, and Gebran et
al. (12) used the MTT assay to quantify bacterial growth
itself. In a series of preliminary experiments, we examined the effect of cleavage of MTT by bacteria in this assay. When bacteria were present in this assay system at less than 107 CFU/well, the
bacteria did not affect the absorbance at 550 nm. The number of
bacteria associated with cell monolayers decreased to less than
2.8 × 104 CFU/ml after the contents of the microplate
were decanted. Thus, cleavage of MTT by bacteria did not influence this
assay. To determine the precise cytopathic effect of the bacteria, we
examined cell death in two groups of control cell monolayers. The first
group consisted of uninfected cell monolayers (control cells with no cytopathic effect), while the second group consisted of cell monolayers treated with 0.1% saponin (control cells with the maximum cytopathic effect). The average cell death of these two controls was defined as
50% cell death, and the corresponding infective dose resulting in 50%
cell death (CPED50) was determined.
Statistical analysis.
Data were expressed as means ± standard deviations (SDs). Differences between groups were tested for
statistical significance by analysis of variance and Schaffe's test. A
P value of less than 0.01 denoted the presence of a
statistically significant difference.
 |
RESULTS |
Intracellular growth of Legionella in J774.1
cells.
A clinical isolate of L. pneumophila,
strain 80-045 SG1, was cultured in 10% FCS-supplemented RPMI 1640 medium alone, medium with J774.1 cell lysates (the contents
corresponding to 1 × 106 cells/ml), or medium with
live J774.1 cells (5 × 105 cells/ml). Bacterial
growth was enhanced in the medium containing live J774.1 cells, while
the number of viable bacteria progressively decreased with time when
the cells were cultured in medium only (Fig.
1). The presence of J774.1 cell lysates
maintained the number of viable bacteria at the baseline level (Fig.
1). The other four clinical isolates (isolates 90-001, 90-002, 91-003, and 97-001) also grew in cultures containing viable J774.1 cells, while
FCS-supplemented RPMI 1640 medium only did not support the growth of
these strains (data not shown).

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 1.
Multiplication of L. pneumophila in J774.1
cells. L. pneumophila SG1 80-045 was cultured in medium
alone (RPMI 1640 plus 5% FCS), the same medium and a lysate of J774.1
cells, or the same medium and live J774.1 cells. The number of viable
bacteria in each well was determined by counting the number of CFU on
BCYE- agar after culture at 35°C for 3 days. Each datum point
represents the mean ± SD for five wells. *, significant
differences (P < 0.01) at 72 h of culture tested
by Schaffe's test. Open circles, medium with live J774.1 cells; open
squares, medium with lysate of J774.1 cells; closed circles, medium
alone.
|
|
Cytopathic effect of L. pneumophila on J774.1
macrophage cells.
To identify the exact site of bacterial growth
in this culture system, the infected J774.1 cell monolayers were
stained with DFA for L. pneumophila SG1 (Fig.
2). Multiplying L. pneumophila was found within the host cells after 36 h of culture (Fig. 2B). The peak growth of Legionella occurred after 72 h of
incubation and resulted in the destruction of the host cells (Fig. 2C).
The cytopathic effect of L. pneumophila against J774.1 cells
was dose dependent (Fig. 3). The
CPED50 of strain 80-045 was approximately 4 × 104 CFU/well, while other strains showed much stronger
cytopathic effects (data not shown).

View larger version (68K):
[in this window]
[in a new window]
|
FIG. 2.
DFA staining of J774.1 cell monolayers. The cell
monolayers were infected with L. pneumophila SG1 80-045 at
1.6 × 106 CFU/well and were cultured for another
72 h. At the indicated time intervals, the culture medium was
discarded and the cell monolayers were stained with
fluorescein-conjugated anti-L. pneumophila SG1 antibody. The
stained samples were examined under a confocal laser scanning
microscope (original magnification, ×600). (A) Control at the time of
infection of J774.1 cell monolayers with L. pneumophila; (B)
36 h after infection; note the presence of replicating bacteria
within the cytoplasms of the J774.1 cells; (C) 72 h after
infection. Note that the majority of the J774.1 cells are destroyed and
that only a few remaining cells are present. Note also that these cells
are filled with bacteria.
|
|

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 3.
Cytopathic effect of L. pneumophila SG1
against J774.1 cell monolayers. J774.1 cells (2 × 104/well) were cultured in a 96-well microplate for 12 h. The cell monolayers were then infected with clinical isolates of
L. pneumophila SG1 at various inoculum sizes. The
microplates were cultured at 37°C for 12 h, and the contents of
the plates were then decanted to remove extracellular medium and
bacteria and new culture medium (200 µl) without any antibiotics was
added to each well. The numbers of viable J774.1 cells after 72 h
of incubation were quantified by the MTT assay and were expressed as
the optical density at 550 nm. Representative results for two strains
are shown. Each point represents the mean ± SD for three wells.
|
|
Comparison of assay of CFU counts and colorimetric MTT assay for
evaluation of intracellular activity against L. pneumophila.
J774.1 macrophage cells were cultured in
96-well microplates and were infected with L. pneumophila
80-045 SG1 at a concentration of 8 × 105 CFU/well (20 times the CPED50). In the next step, a serial fourfold concentration of erythromycin, levofloxacin, or ceftizoxime was added
to Legionella-infected macrophage monolayers. After culture for 72 h, the number of viable bacteria in each well was
determined (Fig. 4). Ceftizoxime at
concentrations of
4 µg/ml did not inhibit the intracellular growth
of the bacteria, and the viable bacterial count was almost similar to
that for the antibiotic-free control. Levofloxacin (
0.063 µg/ml)
was effective in inhibiting bacterial growth, and the CFU counts in all
wells containing levofloxacin were lower than the detection limit of
this assay. The intracellular activity of erythromycin against the
bacteria was concentration dependent, and erythromycin (
4 µg/ml)
significantly inhibited bacterial growth. After 72 h of incubation
the remaining J774.1 cells were also evaluated by the MTT colorimetric
assay under the same conditions used for the CFU count assay, and the
results were expressed as optical densities at 550 nm (Fig.
5). J774.1 cells treated with
levofloxacin (at a concentration of
0.063 µg/ml) survived well,
while treatment with ceftizoxime failed to prevent the death of J774.1
cells. Erythromycin increased the survival of J774.1 macrophage cells
in a dose-dependent manner. As a control for drug-induced cytotoxicity,
these three drugs were also added to macrophage monolayers without
bacterial infection. No direct cytotoxicity of these drugs was observed
in this study (Fig. 5). The optical densities at 550 nm for MTT-treated
J774.1 cells in each experimental group correlated inversely with the number of viable bacteria, indicating that drugs that are effective against the intracellular growth of Legionella also
inhibited the cytopathic effect of intracellularly replicating
bacteria.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 4.
Inhibition of intracellular multiplication of L. pneumophila by antibiotics. Live J774.1 cells were infected with
L. pneumophila SG1 80-045 at 7.8 × 105
CFU/well (20 times the CPED50) for 12 h. After the
extracellular bacteria were washed out, antibiotics were added to the
wells at the indicated concentrations. Bacterial growth after 72 h
of incubation was quantified by counting the numbers of CFU on BCYE-
agar plates. Each column represents the mean ± SD for triplicate
wells. *, significantly different from the control by Schaffe's test
(P < 0.01).
|
|

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 5.
Inhibition by antibiotics of cytopathic effect of
intracellular L. pneumophila. (a) Uninfected live J774.1
cells were treated with antibiotics. (b) Live J774.1 cells were
infected with L. pneumophila SG1 80-045 at 8 × 105 CFU/well (20 times the CPED50) for 12 h. After the extracellular bacteria were washed out, antibiotics were
added to the wells at the indicated concentrations. After 72 h of
culture the remaining J774.1 cells were stained with MTT and the
optical density (OD) of the purple formazan product was quantified at
550 nm. Each column represents the mean ± SD for quadruplicate
wells.
|
|
Determination of intracellular activity of antibiotics against
L. pneumophila.
The intracellular activity of each
antibiotic was evaluated by its ability to inhibit the bacterial
cytopathic effect as described above. J774.1 macrophage cell monolayers
infected with clinical isolates of L. pneumophila SG1 (at 20 times the CPED50) were treated with twofold dilutions of
various antibiotics. On the basis of the results of the experiment
described above, the maximum inhibition of the cytopathic effect
bacterial was obtained when J774.1 cells were treated with levofloxacin
at a concentration of 4 µg/ml, while the minimum inhibition occurred
in the absence of antibiotics. Treatment of
Legionella-infected J774.1 cells with twofold dilutions of
the antibiotics allowed measurement of the dose-response curve of each
drug against the cytopathic effect of the bacteria and determination of
the 50% inhibitory concentration of each drug for the bacterial
cytopathic effect (Fig. 6). As described
above, the MIEC resulting in >50% inhibition of the bacterial
cytopathic effect was defined as the MIEC of each drug, with the MIEC
representing a quantitative indicator of the intracellular activity of
the antibiotic. The MIEC was used to compare the potencies of the various antibiotics. We compared the MICs and the MIECs of 24 different
drugs for strain 80-045 (Table 1). The
MIECs of the beta-lactams and aminoglycosides were markedly higher than
the MICs, while the MIECs of the macrolides, the fluoroquinolones, minocycline, rifampin, and clindamycin were almost similar to the
corresponding MICs. Table 2 summarizes
the MICs and MIECs of the macrolides and fluoroquinolones for strain
80-045 and four other clinical isolates. These results indicate that
clarithromycin was the most potent among the macrolides tested in this
study, with an MIEC of approximately 0.031 µg/ml. All three
fluoroquinolones tested had good intracellular activity against five
clinical isolates of L. pneumophila SG1, and sparfloxacin
was the most potent drug among the fluoroquinolones.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 6.
Dose-response curves demonstrating the effect of
different concentrations of various antimicrobial agents on the
cytopathic effect (CPE) of L. pneumophila 80-045 SG1. J774.1
cells (2 × 104/well) were cultured in 96-well
microplates for 12 h. The cell monolayers were infected with
L. pneumophila 80-045 SG1 (at 8 × 105
CFU/well; 20 times the CPED50) for 12 h. The contents
of the microplates were decanted to remove extracellular medium and
bacteria after culture at 37°C for 12 h, and then new culture
medium (200 µl) containing twofold dilution series of different
antibiotics was added to each well. The viability of the J774.1 cells
was quantified 72 h later by the MTT assay and was expressed as
the optical density at 550 nm. Maximum inhibition of the cytopathic
effect was obtained when J774.1 cells were treated with levofloxacin (4 µg/ml); minimum inhibition of the cytopathic effect was recorded when
no antibiotic was used. The MIEC resulting in >50% inhibition of the
bacterial cytopathic effect was defined as the MIEC of each drug,
representing an indicator of the intracellular activity of the
antibiotic.
|
|
 |
DISCUSSION |
In the present study, we demonstrated that J774.1 cells, a murine
macrophage-like cell line, allowed the intracellular growth of L. pneumophila, as shown previously by Kura et al. (19). DFA staining of infected monolayers indicated that the bacteria replicated within these cells, which subsequently resulted in the
destruction of the host cells. Marra et al. (20) also
described the cytopathic effect of intracellularly replicating
Legionella against host cells using HL-60-derived
macrophages. Our results indicate that the cytopathic effect is dose
dependent and seems to be due to the increased volume of bacteria
replicating within macrophages, as evident on examination of
DFA-stained infected J774.1 monolayers. In addition to the physical
damage caused by replicating bacteria, it is also possible that the
death of these cells was due to a variety of cytotoxins (16)
(e.g., peptide toxin [11]), metalloprotease
(28), and/or apoptosis (24). The number of
remaining host cells, as quantified by the MTT assay, was inversely
proportional to the number of viable replicating bacteria, as evaluated
by CFU assay. These results confirm that the intracellular growth of
Legionella results in host cell death.
Because the cytopathic effect of bacteria on host cells is relevant to
the severity of the disease in vivo (21), the direct assay
system which examines the cytopathic effect of Legionella and its inhibition by antibiotics should provide valuable information and should be a better predictor of the effect of the drug in vivo than
assays that evaluate bacterial growth itself. Thus, the use of the
cytopathic effect assay should be clinically useful for measuring the
in vivo effect of any drug against legionellosis. Although the use of a
human-derived cell line would have been more relevant in the evaluation
and prediction of antibiotic efficacy in humans, our experience
indicates that human cell lines, such as HL-60-derived macrophages
(20) or the U-937 cell line (26), are less
adherent to the bottoms of 96-well plates than the murine macrophage
cell line used in this study (data not shown), making their use
inconvenient when the supernatants were decanted or aspirated from the
cell monolayers.
In this study, we compared the intracellular activities of several
drugs against different strains of L. pneumophila SG1. Our
results indicated that the intraphagocytic activities of beta-lactams and aminoglycosides are markedly lower than the MICs, while the intraphagocytic activities of macrolides, fluoroquinolones, rifampin, and minocycline were comparable. While similar observations have previously been made by other investigators (14, 15, 17, 31,
32), the present study is the first to provide quantitative and
comparative evaluations of these drugs. The activities of aminoglycosides against intracellular Legionella are
controversial (13, 17, 32); however, the present study
clearly indicated a lack of intracellular activity of aminoglycosides
against Legionella. Aminoglycosides failed to cure animals
infected with L. pneumophila (5), and the
extracellular activities of these drugs described in previous studies
(13, 32) may have been misinterpreted as the intracellular
killing of bacteria. This study showed the superior activity of
clarithromycin relative to those of the other macrolides tested, thus
confirming the results of previous in vivo studies of experimental
legionellosis in guinea pigs (10, 18). Our results also
indicated that the intracellular activity of azithromycin is similar to
that of erythromycin, as reported by Edelstein and Edelstein
(7). All fluoroquinolones examined in this study had good
intracellular activity against Legionella, a finding
consistent with the results of previous studies (13, 30).
Sparfloxacin was most potent among the fluoroquinolones tested in this
study, in agreement with our previous study (29) and that of
Edelstein et al. (6). Thus, the results obtained with the
cytopathic effect assay system used in the present study are consistent
with those of previous in vitro and in vivo studies.
Differences between the results of the MTT assay and those of the CFU
assay may exist under certain circumstances. One or more of the
following factors should be considered in such situations: (i)
modulation of cellular viability by antibiotics, (ii) differences in
antibiotic effect on bacterial growth and bacterial cytopathic effect,
and (iii) methodological errors. Methodological errors can be easily
identified when assays are performed three or more times. When
methodological errors are ruled out, the two other possibilities should
be investigated. Further examination of the differences between the two
assays may lead to new information on disease pathogenicity and the
mechanism of drug activity against intracellular L. pneumophila.
In conclusion, the MTT assay described in the present study allows
quantitative and comparative evaluations of intracellular activities of
drugs against Legionella. It may also serve as a valuable
tool for investigating the relationships among bacteria, host
phagocytes, and antimicrobial agents.
We thank F. G. Issa, University of Sydney, Sydney,
Australia, for help in editing the manuscript.
This work was supported in part by Grants-in-Aid for Scientific
Research from the Ministry of Health and Welfare, Japan.
| 1.
|
American Thoracic Society.
1993.
Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy.
Am. Rev. Respir. Dis.
148:1418-1426[Medline].
|
| 2.
|
Denizot, F., and R. Lang.
1986.
Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability.
J. Immunol. Methods
89:271-277[Medline].
|
| 3.
|
Dowling, J. N.,
S. K. Saha, and R. H. Glew.
1992.
Virulence factors of the family Legionellaceae.
Microbiol. Rev.
56:32-60[Abstract/Free Full Text].
|
| 4.
| Edelstein, P. H. 1995. Antimicrobial
chemotherapy for Legionnaires' disease: a review. Clin. Infect. Dis.
21(Suppl. 3):S265-S276.
|
| 5.
|
Edelstein, P. H.,
K. Calarco, and V. K. Yasui.
1984.
Antimicrobial therapy of experimental Legionnaires' disease in guinea pigs.
Am. Rev. Respir. Dis.
130:849-856[Medline].
|
| 6.
|
Edelstein, P. H.,
M. A. C. Edelstein,
J. Weidenfeld, and M. B. Dorr.
1990.
In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia.
Antimicrob. Agents Chemother.
34:2122-2127[Abstract/Free Full Text].
|
| 7.
|
Edelstein, P. H., and M. A. C. Edelstein.
1991.
In vitro activity of azithromycin against clinical isolates of Legionella species.
Antimicrob. Agents Chemother.
35:180-181[Abstract/Free Full Text].
|
| 8.
|
Ezaki, T.,
Y. Hashimoto,
H. Yamamoto,
M. L. Lucida,
S. L. Liu,
S. Kusunoki,
K. Asano, and E. Yabuuchi.
1990.
Evaluation of the microplate hybridization method for rapid identification of Legionella species.
Eur. J. Clin. Microbiol. Infect. Dis.
9:213-217[Medline].
|
| 9.
|
Falco, V.,
T. F. Sevilla, and J. Alegre.
1991.
Legionella pneumophila: a cause of severe community-acquired pneumonia.
Chest
100:1007-1011[Abstract/Free Full Text].
|
| 10.
|
Fernandes, P. B.,
R. Bailer,
R. Swanson,
C. W. Hanson,
E. McDonald,
N. Ramer,
D. Hardy,
N. Shipkowitz,
R. R. Bower, and E. Gade.
1986.
In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide.
Antimicrob. Agents Chemother.
30:865-873[Abstract/Free Full Text].
|
| 11.
|
Friedman, R. L.,
B. H. Iglewski, and R. D. Miller.
1980.
Identification of a cytotoxin produced by Legionella pneumophila.
Infect. Immun.
29:271-274[Abstract/Free Full Text].
|
| 12.
|
Gebran, S. J.,
C. A. Newton,
Y. Yamamoto,
T. W. Klein, and H. Friedman.
1994.
A rapid colorimetric assay for evaluating Legionella pneumophila growth in macrophages in vitro.
J. Clin. Microbiol.
32:127-130[Abstract/Free Full Text].
|
| 13.
|
Havlichek, D.,
L. Saravolatz, and D. Pohlod.
1987.
Effect of quinolones and other antimicrobial agents on cell-associated Legionella pneumophila.
Antimicrob. Agents Chemother.
31:1529-1534[Abstract/Free Full Text].
|
| 14.
|
Higa, F.,
A. Saito,
J. Inadome,
N. Kusano, and K. Kitsukawa.
1993.
Influence of methylprednisolone on the intracellular antimicrobial activity of erythromycin and clindamycin against Legionella pneumophila.
J. Antimicrob. Chemother.
31:901-908[Abstract/Free Full Text].
|
| 15.
|
Horwitz, M. A., and S. C. Silverstein.
1982.
Intracellular multiplication of Legionnaires' disease bacteria (Legionella pneumophila) in human monocytes is reversibly inhibited by erythromycin and rifampin.
J. Clin. Invest.
71:15-26.
|
| 16.
|
Husmann, L. K., and W. Johnson.
1994.
Cytotoxicity of extracellular Legionella pneumophila.
Infect Immun
62:2111-2114[Abstract/Free Full Text].
|
| 17.
|
Kitsukawa, K.,
J. Hara, and A. Saito.
1991.
Inhibition of Legionella pneumophila in guinea pig peritoneal macrophages by new quinolone, macrolide and other antimicrobial agents.
J. Antimicrob. Chemother.
27:343-353[Abstract/Free Full Text].
|
| 18.
|
Kohno, S.,
H. Koga,
K. Yamaguchi,
M. Masaki,
Y. Inoue,
Y. Dotsu,
Y. Masuyama,
T. Hayashi,
M. Hirota,
A. Saito, and K. Hara.
1989.
A new macrolide, TE-031 (A-56268), in treatment of experimental Legionnaires' disease.
J. Antimicrob. Chemother.
24:397-405[Abstract/Free Full Text].
|
| 19.
|
Kura, F.,
K. Suzuki,
H. Watanabe,
Y. Akamatsu, and F. Amano.
1994.
Difference in Legionella pneumophila growth permissiveness between J774.1 murine macrophage-like JA4 cells and lipopolysaccharide (LPS)-resistant mutant cells, LPS1916, after stimulation with LPS.
Infect. Immun.
62:5419-5426[Abstract/Free Full Text].
|
| 20.
|
Marra, A.,
M. A. Horwitz, and H. A. Shuman.
1990.
The HL-60 model for the interaction of human macrophages with the Legionnaires' disease bacterium.
J. Immunol.
144:2738-2744[Abstract].
|
| 21.
|
Marra, A.,
S. J. Blander,
M. A. Horwitz, and H. A. Shuman.
1992.
Identification of a Legionella pneumophila locus required for intracellular multiplication in human macrophages.
Proc. Natl. Acad. Sci. USA
89:9607-9611[Abstract/Free Full Text].
|
| 22.
|
Marrie, J. T.,
H. Durant, and L. Yates.
1989.
Community-acquired pneumonia requiring hospitalization: 5-year prospective study.
Rev. Infect. Dis.
11:586-599[Medline].
|
| 23.
|
Marrie, J. T.,
S. MacDonald, and D. Haldane.
1990.
Nosocomial Legionnaires' disease: lessons from a four-year prospective study.
Am. J. Infect. Control
19:79-85.
|
| 24.
|
Muller, A.,
J. Hacker, and B. C. Brand.
1996.
Evidence for apoptosis of human macrophage-like HL-60 cells by Legionella pneumophila infection.
Infect. Immun.
64:4900-4906[Abstract].
|
| 25.
|
National Committee for Clinical Laboratory Standards.
1993.
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 2nd ed. Tentative standard. NCCLS document M7-T2.
National Committee for Clinical Laboratory Standards, Villanova, Pa.
|
| 26.
|
Pearlman, E.,
A. H. Jiwa,
N. C. Engleberg, and B. I. Eisenstein.
1988.
Growth of Legionella pneumophila in a human macrophage-like (U937) cell line.
Microb. Pathog.
5:87-95[Medline].
|
| 27.
|
Peck, R.
1985.
A one-plate assay for macrophage bactericidal activity.
J. Immunol. Methods
82:131-140[Medline].
|
| 28.
|
Quinn, F. D., and L. S. Tompkins.
1989.
Analysis of a cloned sequence of Legionella pneumophila encoding a 38 kD metalloprotease possessing hemolytic and cytotoxic activities.
Mol. Microbiol.
3:797-805[Medline].
|
| 29.
| Saito, A., and M. Gaja. 1995. In vitro and in vivo
activities of sparfloxacin in Legionella infection. Drugs
49(Suppl. 2):250-252.
|
| 30.
|
Saito, A.,
K. Sawatari,
Y. Fukuda,
M. Nagasawa,
H. Koga,
A. Tomonaga,
H. Nakazato,
Y. Fujita,
Y. Shigeno,
K. Suzuyama,
K. Yamaguchi,
K. Izumikawa, and K. Hara.
1985.
Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental legionella pneumonia in guinea pigs.
Antimicrob. Agents Chemother.
28:15-20[Abstract/Free Full Text].
|
| 31.
|
Vilde, J. L.,
E. Dournon, and P. Rajagopalan.
1986.
Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents.
Antimicrob. Agents Chemother.
30:743-748[Abstract/Free Full Text].
|
| 32.
|
Yoshida, S., and Y. Mizuguchi.
1984.
Antibiotic susceptibility of Legionella pneumophila Philadelphia-1 in cultured guinea pig peritoneal macrophages.
J. Gen. Microbiol.
130:901-906[Medline].
|